^
    20h
    Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations (clinicaltrials.gov)
    P4, N=43, Active, not recruiting, AstraZeneca | Completed --> Active, not recruiting | Trial completion date: Jul 2025 --> Dec 2026
    Enrollment closed • Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • Xtandi (enzalutamide) • abiraterone acetate • prednisone
    1d
    Eprenetapopt in combination with carboplatin in high-grade ovarian and triple negative breast cancer cell lines with acquired resistance to olaparib. (PubMed, Front Oncol)
    Combining eprenetapopt with carboplatin shows promising preclinical efficacy by enhancing cytotoxicity in olaparib-resistant models and demonstrating synergistic interaction; these data support the combination as a potential strategy to mitigate PARPi resistance and carboplatin cross-resistance in TP53 mutant HGSOC and TNBC cell lines. Although further studies are needed to elucidate the molecular mechanisms underlying the synergistic effect, here we point out the combination of eprenetapopt and carboplatin as a potential therapeutic strategy to address olaparib resistance in HGSOC and TNBC patients.
    Preclinical • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ANXA5 (Annexin A5)
    |
    TP53 mutation • BRCA2 mutation • BRCA1 mutation • HRD • TP53 wild-type
    |
    Lynparza (olaparib) • carboplatin • eprenetapopt (APR-246)
    1d
    Interplay between ADP-Ribosylation and Androgen Receptor Function in Prostate Cancer. (PubMed, Curr Pharm Des)
    PARP enzymes regulate AR via MARylation and PARylation, with inhibitors such as Olaparib, which disrupts AR-PARP crosstalk...We also discuss how this complex regulatory network may contribute to the development of advanced prostate cancer therapies in the future. This could improve PARP inhibitor and AR signalling inhibitor combinations and allow more patients to benefit from them.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • TIPARP (TCDD Inducible Poly(ADP-Ribose) Polymerase)
    |
    BRCA mutation
    |
    Lynparza (olaparib)
    3d
    Protein Kinase D1 Translocates PARP1 to the Membrane and Is Associated With Increased Sensitivity to Cell Viability Inhibition by PARP1 Inhibitor Olaparib. (PubMed, Prostate)
    Our study identifies PrKD1 as a novel modulator of sensitivity to olaparib. Co-targeting PrKD1 using small molecular inhibitors may enhance olaparib efficacy at lower doses and improve PARPi tolerability and therapeutic index. The demonstration of PARP1 at the membrane is novel, introducing the possibility of targeting membranous PARP1 for theranostic applications.
    Journal • PARP Biomarker
    |
    PRKD1 (Protein Kinase D1)
    |
    Lynparza (olaparib)
    4d
    Identification of novel drug-specific PARP inhibitor resistance mechanisms in ovarian cancer-implications for clinical practice. (PubMed, Br J Cancer)
    Treatment-induced BCRP/ABCG2 induction is a novel clinically relevant niraparib resistance biomarker. Routine inclusion of paclitaxel in first-line chemotherapy regimens may promote efflux transporter-mediated resistance, compromising response to PARPi maintenance treatment.
    Journal • PARP Biomarker
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2)
    |
    Lynparza (olaparib) • carboplatin • paclitaxel • Zejula (niraparib)
    4d
    Matching-Adjusted Indirect Comparisons of PARP Inhibitor Combinations in Metastatic Castration-Resistant Prostate Cancer Across Key Populations. (PubMed, Oncologist)
    MAICs showed improved clinical benefit with TALA+ENZA versus OLAP+AAP and NIRA+AAP across multiple mCRPC populations and endpoints. Despite limitations of indirect comparisons, findings support TALA+ENZA as a first-line treatment option for mCRPC.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Talzenna (talazoparib) • Zejula (niraparib) • Xtandi (enzalutamide) • abiraterone acetate • prednisone
    4d
    Increasing Use of Germline Genetic Testing in Pancreatic Ductal Adenocarcinoma and Relationship to Clinical Outcome: A Single-Institution Study. (PubMed, JCO Precis Oncol)
    GGT prevalence has increased at RPCCC and informed treatment decisions. Universal point-of-care testing is being implemented with the goal of completing testing for all patients with PDAC seen at RPCCC.
    Clinical data • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSH6 (MutS homolog 6)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    5d
    MOMA-313-001: Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=220, Active, not recruiting, MOMA Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed • First-in-human
    |
    Lynparza (olaparib)
    6d
    The complex landscape of non-coding RNAs in olaparib response and resistance. (PubMed, Cancer Treat Res Commun)
    Subsequently, we explore how olaparib treatment itself can alter the expression profile of ncRNAs, creating a dynamic feedback loop that may influence therapeutic outcome. By consolidating these findings across various cancers, including ovarian, breast, prostate, and hepatocellular carcinoma, this review highlights the potential of ncRNAs as both predictive biomarkers and therapeutic targets to overcome PARPi resistance and enhance patient outcomes.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • RAD51 (RAD51 Homolog A) • STING (stimulator of interferon response cGAMP interactor 1)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib)
    7d
    BRCA mutation status and olaparib-related toxicity during maintenance therapy: a real-world retrospective cohort study. (PubMed, Front Oncol)
    In this real-world retrospective cohort, BRCA mutation status was associated with increased risk of clinically significant olaparib-related toxicity. These findings suggest that BRCA mutation status may help identify patients at higher risk of adverse events and support closer toxicity monitoring and individualized dose management during maintenance therapy.
    Retrospective data • Journal • Real-world evidence • BRCA Biomarker • PARP Biomarker
    |
    BRCA (Breast cancer early onset)
    |
    BRCA wild-type • BRCA mutation
    |
    Lynparza (olaparib)
    8d
    LuPARP: 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours (clinicaltrials.gov)
    P1, N=18, Completed, Vastra Gotaland Region | Active, not recruiting --> Completed
    Trial completion
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate)
    8d
    Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). (clinicaltrials.gov)
    P1/2, N=25, Recruiting, Fundación de investigación HM | Phase classification: P2 --> P1/2
    Phase classification
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate)